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In contrast to early breast cancer, the prognostic effect of tumour angiogenesis in tumours with advanced axillary spread has been less
studied. We retrospectively analysed the effect of microvessel density (MVD) and vascular endothelial growth factor (VEGF) by
immunohistochemistry on the outcome of 215 patients treated uniformly within prospective trials of high-dose chemotherapy for
4–9andX10 positive nodes, and followed for a median of 9 (range 3–13) years. Microvessel density was associated with epidermal
growth factor receptor (EGFR) expression (Po0.001) and tumour size (P¼0.001). Vascular endothelial growth factor
overexpression (51% of patients) was associated with overexpression of EGFR (P¼0.01) and HER2 (Po0.05), but not with
MVD (P¼0.3). High MVD was associated with worse relapse-free survival (74 vs 44%, Po0.001) and overall survival (76 vs 44%,
Po0.001). Vascular endothelial growth factor overexpression had no effect on outcome. Multivariate analyses showed a prognostic
effect of MVD independently of other known prognostic factors in this patient population. In conclusion, tumour angiogenesis,
expressed as MVD, is a major independent prognostic factor in breast cancer patients with extensive axillary involvement.
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High-risk primary breast cancer (HRPBC) is characterised by
extensive axillary involvement, usually defined as four or greater
positive nodes. Although still curable, this stage of the disease
presents a 50% or greater risk of metastatic relapse despite modern
multimodal management. Identification of relevant new biologic
targets in this population may allow for improvement of
therapeutic outcome.
One such type of target might be those involved in tumour
angiogenesis. Angiogenesis promotes tumour growth and meta-
stasis through perfusion of the tumour, facilitation of transport of
tumour cells in the bloodstream, and reciprocal paracrine
stimulation between endothelial and tumour cells (Folkman,
1990; Fidler and Ellis, 1994). Angiogenesis is part of a complex
scenario that also includes tumour suppressor gene and oncogene
pathways, adhesion molecules, apoptosis, and the immune system.
The angiogenic status of a tumour depends on the balance between
proangiogenic and antiangiogenic factors that determines a state of
tumour dormancy, which can last for a long time in breast cancer,
or a predominance of angiogenesis, which appears to trigger
disease progression or relapse.
The vascular endothelial growth factor (VEGF) is one of the
most potent inducers of angiogenesis (Ferrara et al, 2003).
Although it is produced by many different cells, its mitogenic
activity mainly focuses on endothelial cells. Vascular endothelial
growth factor and its tyrosine kinase receptors are subjected to
regulation by tissue oxygen conditions as well as by oncogenes,
such as HER2, or tumour-suppressor genes.
Many studies, but not all, have suggested a prognostic effect of
angiogenesis in early breast cancer, defined by no or limited
axillary involvement. A meta-analysis detected an overall prog-
nostic adverse effect of microvessel density (MVD) among node-
negative patients (Uzzan et al, 2004). The discrepancies among the
studies may be the result of methodological differences or
heterogeneity of patients and treatments. In consequence, it has
been recommended that angiogenesis markers are not to be used
as basis for making clinical decisions (Hayes et al, 2001). The
College of American Pathologists has stated that further study of
quantification of tumour angiogenesis is still required to
demonstrate its prognostic value in breast cancer (Fitzgibbons
et al, 2000).
Furthermore, less is known about the prognostic effect of
angiogenesis in patients with advanced axillary involvement,
who present a higher likelihood of micrometastatic spread at
the time of diagnosis, and, thus, may constitute a different
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sbiological scenario from node-negative tumours. We studied
the effect of tumour angiogenesis in HRPBC by immuno-
histochemical analysis of MVD and VEGF in samples collected
retrospectively from patients who were treated uniformly




This study adhered to the NCI-EORTC guidelines for tumour
marker prognostic studies (McShane et al, 2005). We retro-
spectively analysed tumour samples from patients who were
prospectively enrolled in phase II and III trials of HDC for HRPBC
at the University of Colorado between 1990 and 2001. A total of
234 patients were accrued in these studies, which were open
to patients with 4–9 positive axillary nodes (n¼102) (Bearman
et al, 1997; Moore et al, 2007) and 10 or greater positive nodes
(n¼132) (Nieto et al, 2004; Peters et al, 2005). Those trials, as
well as the current retrospective review of tumour blocks,
were approved by the Cancer Center Protocol Review Committee
and the Institutional Review Board. All patients gave written
informed consent before study entry. Eleven patients (4.7%
of the total enrolment) who died from HDC-related complica-
tions were excluded, leaving 223 patients eligible for this
analysis. Tumour samples could be obtained from 215 of those
223 patients.
Inclusion and exclusion criteria of those trials were similar,
except for the required number of axillary nodes involved. The
studies required adequate visceral organ function. Pretransplanta-
tion staging tests included computed tomographic scans of the
head, chest, abdomen, and pelvis, bone scans, and bone marrow
biopsies. Patients received HDC within 6 months of their primary
surgery (mastectomy or lumpectomy with negative margins).
Patients received four cycles of doxorubicin-containing chemo-
therapy before HDC. Absence of relapse during pretransplantation
chemotherapy was required. Following collection of haematopoietic
progenitor cells, patients received high-dose cyclophosphamide/
cisplatin/carmustine, as described (Peters et al, 2005). Subsequently,
unselected haematopoietic progenitor cells were infused, and
granulocyte colony-stimulating factor was administered until
neutrophil recovery. Post-transplantation treatment included locor-
egional radiotherapy upon platelet recovery. Tamoxifen was
prescribed for 5 years to patients with hormone receptor-positive
tumours.
Immunohistochemical analyses
Paraffin-embedded blocks containing whole-tumour sections from
the surgical specimens were retrospectively obtained from the
referring institutions. All tumour samples were acquired before
initiation of any chemotherapy. Intratumoural microvessels
were identified by immunostaining of formalin-fixed paraffin-
embedded sections with pan-endothelial anti-CD31 monoclonal
antihuman mouse antibody (clone JC/70A; Dako, Carpinteria, CA,
USA) in a 1:40 dilution and overnight incubation. The invasive
tumour component was identified on haematoxylin- and eosin-
stained sections. Intratumoural MVD was then determined as
described previously (Weidner et al, 1991). The area of most
intense neovascularisation was selected by scanning on low
magnification ( 10–100), preferentially on the peripheral tumour
margins. Only the vascularity of tumour areas considered viable,
that is, non-necrotic, was taken into account. Subsequently,
individual microvessels were counted on a  400 field. Any
brown-staining endothelial cell, containing a visible nucleus, and
clearly separate from adjacent microvessels, tumour cells and other
connective-tissue elements, was considered a single, countable
microvessel, without requirement for a lumen or the presence of
erythrocytes. The microvessels were counted in a 0.74-mm
2 area
(i.e., a  400 field). Each patient’s microvessel count was the
average of two separate counts by two different pathologists (SN
and JW) who remained blind to patient outcome.
Vascular endothelial growth factor immunostaining was per-
formed on diagnostic sections using mouse monoclonal antibody
anti-VEGF (C-1; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Vascular endothelial growth factor immunoreactivity was scored
as 0, 1þ,2þ,o r3þ, according to staining intensity (Toi et al,
1994). A tumour area with any degree of staining was scored as
VEGF-positive. Tumours with VEGF-positive and VEGF-negative
areas were assigned the score of the area with strongest staining.
Immunohistochemical analyses of HER2 and p53 used the
monoclonal antibodies CB11 (Vantana Medical Systems, Tucson,
AZ, USA) and DO7 (BioGenex, San Ramon, CA, USA), respec-
tively. The immunohistochemical analysis of epidermal growth
factor receptor (EGFR) employed the murine monoclonal antibody
31G7 (Zymed Laboratories, San Francisco, CA, USA) (1:100
dilution). Staining intensity was evaluated as 1þ (weak), 2þ
(moderate), or 3þ (strong). Cases were graded based on the
overall proportion of cells stained with moderate or strong
intensity: 0, 0% cells; 1þ, 1–33%; 2þ, 34–66%; 3þ, 67–100%.
Cases with X1þ membranous staining for EGFR were considered
positive. Cases with any degree of p53 nuclear staining were
considered positive. We considered HER2-positive those
cases with 2þ (weak complete membrane staining in 410%
of cancer cells) or 3þ grading (intense complete membrane
staining in 410% of cancer cells). All immunostained slides were
reviewed by the same pathologist (SN), who was blinded to patient
outcome.
Statistical methods
Associations between categorical and continuous variables were
assessed using the w
2 or Fisher’s exact test and Student’s t-test,
respectively. Median follow-up times were estimated among
surviving patients. Relapse-free survival (RFS) time was defined
as the time from the administration of HDC to documented relapse
(local, contralateral, or distant) or to death without relapse. Overall
survival (OS) time was defined as the time from HDC to death
from any cause. All survival times were analysed using the
Kaplan–Meier method (Kaplan and Meier, 1958). The log-rank
test was used to study the association of the potential prognostic
variables with survival times (Peto and Peto, 1971). The 25th, 50th,
and 75th percentile of the microvessel counts were evaluated as
potential prognostic cutoffs.
Multivariate analyses of RFS and OS used proportional
hazards Cox regression models (Cox, 1972). These models
included the variables previously identified as independent
prognostic factors in this population: nodal ratio (i.e., no. of
involved axillary nodes/no. of dissected nodes), combined oestro-
gen (ER) and progesterone receptor (PR) status, the pathologic
tumour size and HER2 (Nieto et al, 1999, 2000). The remaining
variables studied, such as age, menopausal status, family history
of breast cancer, histologic grade, tumour ploidy, S-phase
fraction, multifocality, vascular invasion, lymphatic invasion,
extensive intraductal component, or p53 status, which lacked
an independent prognostic effect, were excluded from the
multivariate analyses. Likewise, of all the axillary node-
related variables previously analysed (nodal ratio, absolute
number of involved nodes, presence of involved nodes greater
than 2cm, and extracapsular extension), only the nodal ratio was
independently associated with outcome, and included in the
multivariate models.
The probability of relapse after HDC for HRPBC, based on a
linear regression model with the independent variables, can be
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sexpressed by the following equation (Nieto et al, 1999):
Probability
¼
½expð 3:3844 þ size 0:1418 þ ratio 3:0493   ER=PR 1:149Þ 
1 þ½ expð 3:3844 þ size 0:1418 þ ratio 3:0493   ER=PR 1:1495Þ 
A simpler scoring system was subsequently derived from the
previous formula:
Score¼(nodal ratio 3.05)þ(tumour size 0.15)–(ER/
PR 1.19).
In both formulae, tumour size is entered in centimetres, and
ER/PR status is assigned ‘1’ if positive (i.e., if ER and/or PR are
positive) and ‘0’ if negative (i.e., if both ER and PR are negative).
The patient is assigned the high or low risk of relapse category if
the score is X2.41 or o2.41, respectively, with highly significant
differences in RFS (Po10
 5) and OS (Po10
 5) between both
groups. The optimal cutoff score of 2.41, as identified in the
receiver operating characteristic curves, conferred on the model a
sensitivity of 0.6, a specificity of 0.88, a positive predictive value of
0.65, a negative predictive value of 0.86, and an accuracy of 83%.
The prognostic value of this score was confirmed externally (Nieto
et al, 1999) and prospectively (Nieto et al, 2004).
The significance of the current multivariate models was
evaluated with the likelihood ratio test. Individual coefficients
were tested using Wald’s statistic. The proportionality assumption
for the variables was assessed with Kaplan–Meier curves. All
P-values presented are two-tailed. All statistical analyses were
carried out using Statview 5.01 software (SAS Institute, Cary, NC,
USA).
RESULTS
We studied specimens from 215 patients (96% of the eligible
population of 223 patients) (Table 1). CD31 staining of tumour
vessels is shown in Figure 1A. The median microvessel count was 8
per field (range, 2–27), with low (6%) interobserver variation. The
microvessel count was higher in tumours overexpressing EGFR
than in EGFR-negative tumours (11.5 vs 6; Po0.001), and in
tumours 42cm than in those p2cm (10 vs 6.5; P¼0.001). In
contrast, we did not observe an association between MVD and
HER2 status (median microvessel counts for HER2-positive and
HER2-negative tumours of 8 and 7, respectively, P¼0.5), nodal
status (expressed as either the nodal ratio (P¼0.8), or the absolute
number of positive nodes (P¼0.4)), p53 status (P¼0.9), or
histologic grade (P¼0.8). Finally, there was a nonsignificant trend
for a higher microvessel count in ER/PR-negative than in ER/PR-
positive tumours (8.5 vs 7; P¼0.09).
Intratumoural VEGF expression was detected in 51% of the
patients (Figure 1B). Its staining intensity was graded as 1þ in 29
(26%) patients, as 2þ in 44 (40%) patients, and as 3þ in 37 (34%)
patients. No correlation was seen between MVD and VEGF
expression (P¼0.3). Vascular endothelial growth factor over-
expression was detected in 56% of the patients with HER2-positive
tumours, compared with 39% of those with HER2-negative
tumours (P¼0.04). Likewise, 61% of patients with EGFR-positive
tumours coexpressed VEGF, compared with 39% of those with
EFGR-negative tumours (P¼0.01). Vascular endothelial growth
factor was not associated with the nodal ratio (P¼0.8), the
absolute number of positive nodes (P¼0.6), tumour size (P¼0.6),
ER/PR status (P¼0.6), p53 status (P¼0.9), or histologic grade
(P¼0.7).
Prognostic analyses
We identified a prognostic cutoff count of 14 microvessels (75th
percentile). The RFS rates in patients with low and high MVD were
74% (95% confidence interval (CI), 67–80%) and 44% (95% CI,
36–51%), respectively (Po0.001) (Figure 2A). Their respective OS
rates were 76% (95% CI, 69–82%) and 44% (95% CI, 36–51%)
(Po0.001) (Figure 2B).
In contrast, the groups with VEGF-positive and VEGF-negative
tumours did not have significantly different RFS (71.5 vs 70%,
P¼0.8, Figure 3A) or OS (75 vs 70%, P¼0.4). Analysing VEGF
expression according to its semiquantitated grading found no
significant outcome differences between the groups with 0, 1þ,
2þ,o r3 þ staining, with RFS rates of 69, 79, 64, and 78%,
respectively (P¼0.4) (Figure 3B).
Multivariate analyses
Multivariate models included MVD, HER2, and the three
independent clinical variables, nodal ratio, tumour size, and ER/
PR status. Model 1 included the clinical variables combined as the
score. Model 2 analysed all variables separately. Both models
showed the independent prognostic effect of MVD on RFS and OS
(Table 2).




















No. of dissected nodes: median, range 19 (10–46)





Low (o2.41) 151 (70)














ER¼oestrogen receptors; nodal ratio¼number of involved nodes/number of
dissected nodes; PR¼progesterone receptors.
aER/PR¼‘1’ if positive and ¼‘0’ if
negative.
bPredictive score¼(nodal ratio 3.05)+(tumour size 0.15) ER/PR 1.15.
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sThe combined analysis of MVD and the clinical score offered a
highly significant separation of four prognostic categories
(Po10
 5) (Figure 4A). Patients with a high score and a low
MVD had significantly better RFS than those with a high score and
a high MVD (55 vs 0%, P¼0.005). Within the low-score subgroup,
however, the differences between patients with low and high MVD
approached but did not reach the level of statistical significance
(83 vs 74%, P¼0.09).
Combining MVD and HER2 resulted in the following four
prognostic groups (Po0.0001): (1) HER2 negativity and low MVD
(78% RFS), (2) HER2 negativity and high MVD (67% RFS), (3)
HER2 positivity and low MVD (66% RFS), and (4) HER2 positivity
and high MVD (21% RFS). Merging groups 2 and 3 results in a
three-group classification based on the presence of 0, 1, or 2 of
those poor-risk features (P¼0.00001) (Figure 4B).
DISCUSSION
In this study, we found that a highly angiogenic phenotype,
determined by MVD, was a powerful adverse prognostic factor in
our group of 215 patients with HRPBC treated with uniform
multimodal treatment including HDC. The effect of MVD was
independent of other known prognostic factors in this patient
population. Tumour microvessels were counted separately by two
different pathologists following the international consensus guide-
lines on angiogenesis quantification (Vermeulen et al, 1996), with
low interobserver variability.
Although HER2 signaling is believed to promote tumour
angiogenesis (Kumar and Yarmand-Bagheri, 2001), we found no
association between HER2 overexpression and MVD, in keeping
with previous results (Vogl et al, 2006). In contrast, others
observed an association of MVD and HER2 overexpression in
small series of patients with node-negative disease (Koukourakis
et al, 2003). We noted a significant association between HER2 and
VEGF, as did previous studies of mixed populations with node-
negative and node-positive tumours (Konecny et al, 2004;
Linderholm et al, 2004). We considered it important that the
prognostic effects of tumour angiogenesis and HER2 in our study
were mutually independent, suggesting the potential benefit of
their concurrent targeting in this population. The feasibility of
dual VEGF and HER2 targeting with bevacizumab and trastuzu-
mab has been recently shown (Pegram et al, 2004), and could be
tested in HRPBC patients.
Another interesting observation was the association between
MVD or VEGF and EGFR. Activation of EGFR signaling
upregulates VEGF and activates angiogenesis in human brain
cancer cells (Goldman et al, 1993). An association of EGFR with
MVD in breast cancer was previously suggested in a small study of
45 patients (De Jong et al, 1998).
In contrast to MVD, we did not observe any significant
prognostic effect of VEGF, one of the most potent inducers of
angiogenesis. As such, it constitutes a major target for strategies
A
B
Figure 1 Immunohistochemical staining. (A) Intratumour CD31-stained
microvessels. (B) VEGF staining.
































Figure 2 Outcome according to MVD, according to a cutoff 14 microvessels (75th percentile). (A) Relapse-free survival; (B) overall survival.
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saiming at disrupting angiogenesis. Indeed, the most successful
antiangiogenic intervention to date has been the use of bevacizu-
mab in metastatic breast cancer (Miller et al, 2005), colorectal
cancer (Hurwitz et al, 2004), and non-small-cell lung cancer
(Sandler et al, 2006). However, its usefulness as a potentially
informative prognostic marker is a separate issue from its
value as a therapeutic target. Similar to previous observations
in breast cancer (Lantzsch et al, 2002; Chhieng et al, 2003),
we observed no significant association between VEGF expres-
sion and MVD, supporting the notion that multiple angiogenic
factors, besides VEGF, play a role in the angiogenic process.
Redundancy is a major characteristic of tumours, and different
angiogenesis markers may be relevant in different phases of
development.
Our study has several potential limitations. One is the inherent
bias in all retrospective studies of archival tissue which may be
lessened in this study by the high sample collection rate. Another
limitation is the fact that all patients analysed received HDC, which
02468 1 0 1 2 1 4
Years
































Figure 3 Lack of effect of VEGF expression on RFS. (A) Expressors vs non-expressors (P¼0.8). (B) According to semiquantitated grading (P¼0.4).
Table 2 Multivariate models
Relapse-free survival Overall survival
Model 1 Model 2 Model 1 Model 2
Variable
Odds ratio
(95% CI) P-values Variable
Odds ratio
(95% CI) P-values Variable
Odds ratio




a 2.7 (2–3.4) 0.005 MVD
a 2.4 (1.7–3.1) 0.01 MVD
a 3.0 (2.3–3.7) 0.002 MVD
a 2.6 (1.9–3.3) 0.008
HER2
b 2 (1.5–2.6) 0.001 HER2
b 1.7 (1.2–2.3) o0.05 HER2
b 2.0 (1.4–2.5) 0.02 HER2
b 1.66 (1.2–2.25) o0.05
Score
c 2.1 (1.6–2.7) o0.05 Nodal ratio
d 2.2 (1.7–2.8) o0.01 Score
c 2.2 (1.7–2.8) 0.005 Nodal ratio
d 2.2 (1.6–2.8) 0.01
Tumour size
e 1.4 (0.95–2) 0.08 Tumour size
e 1.5 (0.9–2.15) 0.1
ER/PR
f 0.29 (0.1–0.9) o0.05 ER/PR
f 0.3 (0.04–0.9) o0.05
CI¼confidence interval; ER¼oestrogen receptors; MVD¼microvessel density; PR¼progesterone receptors.
aMVD: 414 vs p14.
bHER2: positive vs negative.
cPredictive
score (high vs low)¼(nodal ratio 3.05)+(tumour size 0.15) (ER/PR 1.15). ER/PR¼‘1’ if positive and¼‘0’ if negative. Scores o2.41 are low, scores X2.41 are high.
dNodal ratio (X0.8 vs o0.8)¼number of involved nodes/number of dissected nodes.
eTumour size: X5 vs o5cm.
fER/PR status: positive vs negative.
Years
0.0

























Low score, low MVD
High score, low MVD
High score, high MVD
Low score, high MVD
HER2-negative and low MVD
HER2-positive or high MVD
HER2-positive and high MVD
P=10−5
Figure 4 Relapse-free survival combining MVD and other independent prognostic variables. (A) Analysis of MVD (cutoff, 14 microvessels – 75th
percentile) and the predictive score (cutoff score, 2.41). (B) Analysis of MVD and HER2 status.
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sis not currently part of the standard management of HRPBC.
Although significant superiority of HDC over standard-dose
chemotherapy has been seen in some randomised trials (Roche ´
et al, 2001; Nitz et al, 2005), several other studies have not shown
any appreciable outcome differences (Tallman et al, 2003; Leonard
et al, 2004; Coombes et al, 2005; Peters et al, 2005; Moore et al,
2007). In addition, our analysis excluded those patients who
relapsed during pretransplantation chemotherapy and never
received HDC, which could represent a selection bias. However,
this very poor prognosis subgroup represented only 2% of all
patients enrolled in those trials (Peters et al, 2005).
In conclusion, tumour angiogenesis, expressed as MVD but not
as VEGF, was found to be a major independent prognostic factor in
patients with HRPBC treated with HDC. These results support the
evaluation of antiangiogenic interventions in this high-risk
population.
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